Psychoactive substance use in patients diagnosed with attention-deficit/hyperactivity disorder: an exploratory study
- PMID: 37496681
- PMCID: PMC10366592
- DOI: 10.3389/fpsyt.2023.1184023
Psychoactive substance use in patients diagnosed with attention-deficit/hyperactivity disorder: an exploratory study
Abstract
Introduction: Attention-deficit/hyperactivity disorder (ADHD) was originally treated as a neurodevelopmental disorder that occurs mainly in children and tends to diminish or disappear with age, but we now know that symptoms persist into adulthood in over 50% of ADHD patients. Undiagnosed individuals often turn to psychoactive substance to minimize the negative aspects of functioning and improve quality of life.
Methods: The study was conducted online using random sampling through a Facebook group administered by physicians and targeted to patients diagnosed with ADHD. The study was naturalistic and exploratory, therefore no hypothesis was made. 438 correctly completed questionnaires were received. Analysis of the results showed that people with ADHD turn to psychoactive substances relatively frequently.
Results: The most commonly used stimulants include alcohol, marijuana, 3,4-methylenedioxymethamphetamine (MDMA), amphetamine/methamphetamine, and psilocybin. In the study population, methylphenidate is the most commonly used drug among patients. After treatment with psychostimulants, the majority of respondents note a decrease in symptoms of hyperactivity disorder, especially in male patients.
Conclusion: It is necessary to perform proper diagnostics and actively look for ADHD symptoms in patients who tend to use psychoactive substances.
Keywords: ADHD; addiction; addiction psychiatry; psychoactive substance; psychoactive substance abuse.
Copyright © 2023 Więckiewicz, Stokłosa, Stokłosa, Więckiewicz, Gorczyca and Gondek.
Conflict of interest statement
GW received honoraria for lectures from: Angelini Pharma Polska and support for attending meetings from: Angelini Pharma Polska, Apotex Poland/Aurovitas Pharma Polska, Lek-AM. IS received support for attending meetings from: Lek-AM. TG received honoraria for lectures from: Valeant Polska, Lundbeck Poland, Apotex Poland/Aurovitas Pharma Polska, Celon Pharma and support for attending meetings from: Lundbeck Poland, EGIS, GL Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Prevalence of attention deficit hyperactivity disorder in individuals with psychoactive substance dependence.Psychiatriki. 2025 May 14. doi: 10.22365/jpsych.2025.010. Online ahead of print. Psychiatriki. 2025. PMID: 40400270
-
Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers.J Clin Psychiatry. 2000 Apr;61(4):244-51. doi: 10.4088/jcp.v61n0402. J Clin Psychiatry. 2000. PMID: 10830144
-
[Supervised off-label prescribing of methylphenidate in adult ADHD].Encephale. 2019 Feb;45(1):74-81. doi: 10.1016/j.encep.2018.05.008. Epub 2018 Aug 16. Encephale. 2019. PMID: 30122296 French.
-
[Adult attention deficit hyperactivity disorder (ADHD) with comorbid addictive disorder. Therapeutic challenges using the example of a survey of clinical practice].MMW Fortschr Med. 2019 Jul;161(Suppl 5):7-12. doi: 10.1007/s15006-019-0740-0. Epub 2019 Jul 16. MMW Fortschr Med. 2019. PMID: 31313269 Review. German.
-
Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder (ADHD) in adults.Encephale. 2020 Feb;46(1):30-40. doi: 10.1016/j.encep.2019.06.005. Epub 2019 Oct 11. Encephale. 2020. PMID: 31610922 Review.
Cited by
-
Gender differences in ADHD and impulsivity among alcohol or alcohol- and cocaine-dependent patients.Front Psychiatry. 2025 Feb 27;16:1446970. doi: 10.3389/fpsyt.2025.1446970. eCollection 2025. Front Psychiatry. 2025. PMID: 40084061 Free PMC article.
References
LinkOut - more resources
Full Text Sources